Advanced search×

On the toxicity of therapeutically used nanoparticles: an overview.

J Toxicol (2009) PMID 20130771

Human beings have been exposed to airborne nanosized particles throughout their evolutionary stages, and such exposures have increased dramatically over the last century. The rapidly developing field of nanotechnology will result in new sources of this exposure, through inhalation, ingestion, and injection. Although nanomaterials are currently being widely used in modern technology, there is a serious lack of information concerning the human health and environmental implications of manufactured nanomaterials. Since these are relatively new particles, it is necessary to investigate their toxicological behavior. The objective of this review was to trace the cellular response to nanosized particle exposure. Therapeutic application of selected nanoparticles together with their range of toxic doses was also reviewed. Effect of therapeutically used nanoparticles on cell membrane, mitochondrial function, prooxidant/antioxidant status, enzyme leakage, DNA, and other biochemical endpoints was elucidated. This paper highlights the need for caution during the use and disposal of such manufactured nanomaterials to prevent unintended environmental impacts.

DOI: 10.1155/2009/754810
Version: za2963e q8za2 q8zbc q8zcc q8zdf q8zeb q8zf8 q8zg4

Similar articles you may find interesting…

  1. Oral Delivery of Low Molecular Weight Heparin by Polyaminomethacrylate Coacervates.

    Pharm Res (2013) PMID 23649851

    CAs prepared by an organic solvent-free method allowed the oral delivery of LMWHs. The therapeutic efficiency and the simple and solvent-free manufacturing process underlines the high potential of this new preparation method....
  2. Antiglaucoma carbonic anhydrase inhibitors: a patent review.

    Expert Opin Ther Pat (2013) PMID 23627893

    Glaucoma is one of the major causes of blindness, affecting together with age-related macular degeneration > 70 million people worldwide. One of the therapeutic options for its management is based on the inhibition of the metalloenyme carbonic anhydrase (CA, EC 4.2.1.1). CA inhibitors (CAIs) diminis...
  3. Novel Pharmacotherapies of Familial Hyperlipidemia.

    Pharmacol Ther (2013) PMID 23639874

    Familial hyperlipidemia is an inherited metabolic disorder characterized by elevated lipid and/or lipoprotein levels in the blood. Despite improvements in lipid-lowering therapy during the last decades, it still remains a substantial contributor to the incidence of cardiovascular dis...